ProShare Advisors
NERV icon

ProShare Advisors’s Minerva Neurosciences NERV Stock Holding History

ProShare Advisors’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,742
Closed -$108K – 1797
2019
Q3 		$108K Sell
1,742
-87
-5% -$4.93K ﹤0.01% 1537
2019
Q2 		$82K Sell
1,829
-238
-12% -$11.9K ﹤0.01% 1548
2019
Q1 		$130K Buy
2,067
+17
+0.8% +$1.02K ﹤0.01% 1543
2018
Q4 		$111K Sell
2,050
-395
-16% -$28.9K ﹤0.01% 1461
2018
Q3 		$245K Sell
2,445
-94
-4% -$7.06K ﹤0.01% 1478
2018
Q2 		$168K Sell
2,539
-121
-5% -$7.35K ﹤0.01% 1645
2018
Q1 		$133K Sell
2,660
-438
-14% -$21K ﹤0.01% 1605
2017
Q4 		$150K Sell
3,098
-145
-4% -$7.19K ﹤0.01% 1690
2017
Q3 		$197K Buy
3,243
+610
+23% +$35K ﹤0.01% 1288
2017
Q2 		$186K Buy
2,633
+37
+1% +$2.4K ﹤0.01% 1357
2017
Q1 		$168K Sell
2,596
-660
-20% -$51.3K ﹤0.01% 1470
2016
Q4 		$306K Buy
+3,256
New +$332K ﹤0.01% 1348

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
IVAI
Index Venture Associates IV St. Helier, Channel Islands, Jersey $6.24M AUM
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

ProShare Advisors's NERV Position: Q4 2019 in Review

ProShare Advisors sold out of Minerva Neurosciences (NERV) in Q4 2019, closing a stake of 1,742 shares — an estimated $108K sold.

ProShare Advisors first reported a position in NERV in Q4 2016 and held it in 12 quarters. The position peaked at $306K in Q4 2016. 92 funds tracked by Wall St. Rank hold NERV as of Q4 2019.

  • ProShare Advisors reported no remaining Minerva Neurosciences position as of Q4 2019 after selling out during the quarter.
  • ProShare Advisors sold 1,742 Minerva Neurosciences shares in Q4 2019, an estimated $108K.
  • ProShare Advisors first reported a position in Minerva Neurosciences in Q4 2016 and held it in 12 quarters.
  • ProShare Advisors's Minerva Neurosciences position peaked at $306K in Q4 2016.
  • 92 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q4 2019.

Based on ProShare Advisors's 13F filing for Q4 2019, filed 12 Feb 2020.